Renata set to pay off short-term loans with bond finance
Each bond unit will have a face value of Tk1 lakh
In a strategic move to mitigate the potential impact of rising interest rates, Renata Limited – a leading drugmaker in the country – is poised to issue bonds to entirely pay off its outstanding short-term bank loans.
Currently, the company acknowledges an indebtedness of around Tk700 crore to several banks in the form of short-term credits.
On Thursday, the Bangladesh Securities and Exchange Commission (BSEC) granted approval for Renata to issue a five-year bond worth Tk660.15 crore.
Each bond unit will have a face value of Tk1 lakh.
Keep updated, follow The Business Standard's Google news channel
The issuance is designated for banks, non-bank financial institutions, insurance companies, institutional investors, and high-net-worth individuals through private placement.
Jubayer Alam, company secretary at Renata Limited, told The Business Standard, "Due to the potential risk of increasing interest rates on bank borrowings, the company's management has opted to fully repay the loans through bond financing. The alternative avenue for long-term financing will enable the company to minimise its finance expenses."
He continued, "Currently, lending rates at banks are on the rise. Consequently, finance costs may escalate in the future. By securing financing through bonds with fixed rates, we anticipate obtaining funds at a lower rate compared to the potential future interest rates."
In its report for the fiscal 2022-23, the company said its debt positions were predominantly short-term, exposing it to liquidity and interest rate risks.
"Long-term bank financing mitigates liquidity risk; however, banks reserve the right to re-set rates periodically. As a result, given our high level of credit-worthiness and balance sheet strength, to fully mitigate interest rate risk, we are now in the process of raising a total of Tk700 crore for balance sheet restructuring," read the report.
Besides the issuance of the bond, Renata has decided to issue redeemable cumulative non-convertible and non-participative preference shares to raise Tk350 crore to refinance the existing loans.
In this line, the company secured approval from its shareholders in the annual general meeting (AGM).
Jubayer Alam said, "Basically, we have Tk700 crore in short-term loans in banks. We have secured a bond; now we need over Tk200 crore to repay the full loans."
Preference shares are shares of a company's stock with dividends that are paid out to shareholders before common stock dividends are issued.
If the company goes bankrupt, preferred stockholders are entitled to be paid from company assets before common stockholders.
While the non-participating preferred shares, for which dividends are usually paid at a fixed rate and not determined by a company's earnings. The shareholders of this type of share do not participate in the distribution of profits to equity investors.
According to its annual reports, Renata logged the lowest profit in the fiscal 2022-23 since the fiscal 2014-15.
The company reported a profit of Tk233 crore in FY23, reflecting a decline of over 54% from the previous fiscal year, attributed to the recent hikes in raw materials and utility costs.
In its annual report addressing the decline in profits, the company noted an overall surge in raw material costs, escalating by 20%-25%. Additionally, the electricity price saw three increases of 5% each during the year, leading to a compounded increase of 15.7%.
Furthermore, diesel prices rose by 37%, and furnace oil prices experienced a hike of 41.4%. As a result, the company observed a substantial 72% increase in energy costs.
As a result of lower profits, the company recommended a reduced dividend compared to the previous year. It declared a 62.5% cash dividend for the fiscal 2022-23, a decrease from the 140% cash and 7% stock dividends declared a year ago.
Recently, Renata has expanded its footprint into the Australian pharmaceutical market for the first time.
As part of its increasing footprint in the global market, the drugmaker, at the beginning of December last year, entered into an agreement with Nova Pharmaceuticals Australasia Pty Ltd to distribute contraceptive pills.
According to its annual report, at present, Renata has been exporting its products to 47 countries, with two more countries in process. A year ago, Renata exported its products to 25 countries.
Renata Limited was founded in 1972 as Pfizer Laboratories (Bangladesh) and has since grown to become a major player in the domestic and international markets.
Renata manufactures a wide range of pharmaceutical products, including antibiotics, anti-inflammatories, analgesics, vitamins, neurological products, anti-diabetics, and anti-cancer products.
Major export destinations include Denmark, Myanmar, Pakistan, Sri Lanka, Ireland, and the United Kingdom, which represent 50% of its exports, with a further 11.7% of shipments to various African countries, according to its latest report.
Renata continued to rank among the top five pharmaceuticals in Bangladesh, with a market share of 7% in 2023.
Among the 671 pharmaceutical products, Ranata's top 20 products continue to represent 72% of pharmaceutical sales.
Moreover, new products targeting non-communicable diseases are contributing to a greater share of growth. While in animal health, it continued to be the market leader with a growth of 11.4% vs the market growth of 9.09% in 2023.
